» Articles » PMID: 11091204

Ontogeny of Natural Killer Cells and T Cells by Analysis of BCR-ABL Rearrangement from Patients with Chronic Myelogenous Leukaemia

Overview
Journal Br J Haematol
Specialty Hematology
Date 2000 Nov 25
PMID 11091204
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic myelogenous leukaemia (CML) is a haematological malignant disorder characterized by the Philadelphia chromosome (Ph) and BCR-ABL gene rearrangement. This abnormal fusion gene can be considered to serve as a marker for the transformed cell clone in CML and is found in all cells arising from the same malignant precursor cell. It has been detected in CML cells of the myeloid, monocytic, erythroid and B-lymphocytic lineages. However, it is still arguable as to whether T lymphocytes or natural killer (NK) cells carry this marker. Answering this question would clarify the ontogenic relationship between NK cells and T cells. We examined 12 CML patients and studied the expression of BCR-ABL rearrangement by fluorescence in situ hybridization (FISH) in both NK cells and T cells sorted by flow cytometry. The purity of T cells was 95.6-99.8% and that of NK cells was 95.3-99.3% after sorting. Neither NK cells nor T cells showed any positive BCR-ABL signal with the exception of one patient who recovered from a lymphoid blastic crisis. We speculate that T cells and NK cells originate from BCR-ABL-negative stem cells.

Citing Articles

Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia.

Kuznetsova V, Krishnan V, Costa A, Ren X, Ricketts T, Patel S Blood Adv. 2024; 9(4):759-773.

PMID: 39571169 PMC: 11869968. DOI: 10.1182/bloodadvances.2024014592.


NK Cells in Myeloproliferative Neoplasms (MPN).

Naismith E, Steichen J, Sopper S, Wolf D Cancers (Basel). 2021; 13(17).

PMID: 34503210 PMC: 8431564. DOI: 10.3390/cancers13174400.


Ontogeny of human B1 cells.

Kageyama Y, Katayama N Int J Hematol. 2019; 111(5):628-633.

PMID: 31721035 DOI: 10.1007/s12185-019-02775-y.


Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Carlsten M, Jaras M Front Immunol. 2019; 10:2357.

PMID: 31681270 PMC: 6797594. DOI: 10.3389/fimmu.2019.02357.


NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.

Sopper S, Mustjoki S, Gjertsen B, Giles F, Hochhaus A, Janssen J Leukemia. 2017; 31(10):2264-2267.

PMID: 28744011 DOI: 10.1038/leu.2017.235.